We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Informatics

Informatics

EpicentRx

EpicentRx is an innovation-driven clinical-stage drug and device company that puts the emphasis on “ease” – ease of treatment, ease of side effects and ease of symptoms during the treatment of a range of diseases including lung cancer, head and neck cancer and different inflammatory disorders for which the company has received several grants and orphan designations.

Latest Content

EpicentRx Receives Fast Track Designation From the U.S. FDA for Lead Asset

EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

Radioactive symbol.

Industry Insight

The Case for RRx-001 as a Radiation Countermeasure

This article overviews the science behind the potential use of RRx-001as a “radiation buster” with anti-inflammatory and anti-free radical properties to prevent or reduce both GI-ARS and H-ARS.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter